A vast number of small-molecule ligands, including therapeutic drugs under development and in clinical use, elicit their effects by binding specific proteins associated with the genome. An ability to map the direct interactions of a chemical entity with chromatin genome-wide could provide important insights into chemical perturbation of cellular function. Here we describe a method that couples ligand-affinity capture and massively parallel DNA sequencing (Chem-seq) to identify the sites bound by small chemical molecules throughout the human genome. We show how Chem-seq can be combined with ChIP-seq to gain unique insights into the interaction of drugs with their target proteins throughout the genome of tumor cells. These methods will be broadly useful to enhance understanding of therapeutic action and to characterize the specificity of chemical entities that interact with DNA or genome-associated proteins.
l e t t e r s
A vast number of small-molecule ligands, including therapeutic drugs under development and in clinical use, elicit their effects by binding specific proteins associated with the genome. An ability to map the direct interactions of a chemical entity with chromatin genome-wide could provide important insights into chemical perturbation of cellular function. Here we describe a method that couples ligand-affinity capture and massively parallel DNA sequencing (Chem-seq) to identify the sites bound by small chemical molecules throughout the human genome. We show how Chem-seq can be combined with ChIP-seq to gain unique insights into the interaction of drugs with their target proteins throughout the genome of tumor cells. These methods will be broadly useful to enhance understanding of therapeutic action and to characterize the specificity of chemical entities that interact with DNA or genome-associated proteins.
The ability to map the locations of proteins throughout the genome has had a profound impact on our understanding of a wide range of normal and disease biology. For example, discovery of the genomewide location of proteins by means of chromatin immunoprecipitation (ChIP)-seq has allowed global mapping of the key transcription factors and chromatin regulators that control gene expression programs in various cells, the sites that act as origins of DNA replication, and regions of the genome that form euchromatin and heterochromatin [1] [2] [3] [4] [5] [6] . Models of the transcriptional regulatory circuitry that controls normal and disease states in cells have emerged from genome-wide data [7] [8] [9] [10] .
Mapping the global interactions of a chemical entity with chromatin genome-wide could provide insights into the mechanisms by which a small molecule influences cellular functions. Many DNA-associated processes are targeted for disease therapy, including transcription, modification, replication and repair [11] [12] [13] [14] [15] [16] . Ligand-affinity methodologies have greatly contributed to our understanding of drug and ligand function, and have led to the identification of numerous gene regulatory drug targets [17] [18] [19] [20] . There have been initial efforts to map the sites of interaction of metabolic compounds in the yeast genome 21 , but it would be ideal to have a method that allows investigators to determine how small-molecule therapeutics interact with the human genome. We describe here a method based on chemical affinity capture and massively parallel DNA sequencing (Chem-seq) that allows investigators to identify genomic sites where small chemical molecules interact with their target proteins or DNA (Fig. 1a) . The Chem-seq method is similar to that employed for ChIP-seq, except that Chem-seq uses retrievable synthetic derivatives of a compound of interest to identify sites of genome occupancy whereas ChIP-seq uses antibodies against specific proteins for this purpose.
We used Chem-seq to investigate the genome-wide binding of the bromodomain inhibitor JQ1 to the BET bromodomain family members BRD2, BRD3 and BRD4 in MM1.S multiple myeloma cells. JQ1 has previously been shown to bind all three co-activator proteins and to inhibit the growth of MM1.S and other tumor cells 13, [22] [23] [24] [25] [26] [27] . We first investigated how BRD2, BRD3 and BRD4 occupy the genome of MM1.S cells using ChIP-seq (Supplementary Fig. 1 ). All three proteins were found to be associated with actively transcribed genes ( Supplementary Fig. 1a) . Inspection of individual gene tracks (Supplementary Fig. 1b ) and analysis of global genome occupancy ( Supplementary Fig. 1c) showed that most core promoter elements of active genes were co-occupied by BRD2, BRD3 and BRD4 together with RNA polymerase II (RNA Pol II), the Mediator complex subunit 1 (MED1) and histone H3K27Ac. In contrast, enhancers, which are occupied by histone H3K27Ac and Mediator, were preferentially occupied by BRD4, with lower relative levels of BRD2 and BRD3.
To investigate the interaction of JQ1 with chromatin genome-wide, we used the Chem-seq technique (Fig. 1a) with a biotinylated derivative of JQ1 (bio-JQ1, Fig. 1b) . Enantioretentive substitution at C-6 of the JQ1 diazepine allowed coupling of a polyethylene glycol spacer with appended biotin feature. The potency of bio-JQ1 binding to the first bromodomain of BRD4 was nearly equivalent to that of the unbiotinylated compound, as determined by both differential scanning fluorimetry and isothermal titration calorimetry ( Supplementary  Fig. 2) . Consistent with this, bio-JQ1 had only slightly reduced bioactivity in MM1.S cells relative to JQ1 (Fig. 1c) . We initially treated living cells with bio-JQ1 and cross-linked proteins to DNA with formaldehyde (Fig. 1a) . Cells were then lysed and sonicated to shear the DNA, and streptavidin beads were used to isolate biotinylated ligand and associated chromatin fragments. Massively parallel sequencing was used to identify enriched DNA fragments, and these sequences were mapped to the genome to reveal sites bound by the smallmolecule probe.
In addition, we developed an in vitro version of this method, which allows analysis of biotinylated molecules with potentially l e t t e r s limited cell permeability (Fig. 1a) . To this end, MM1.S cells were fixed and the derived sonicated lysate incubated with biotinylated JQ1 to enrich for bound chromatin regions in vitro.
We found that both in vivo and in vitro Chem-seq produced essentially the same result: the genomic sites bound by biotinylated JQ1 are highly similar to the sites occupied by BRD2, BRD3 and BRD4 (Fig. 1d,e) . This was further confirmed by inspection of data at individual genes with pivotal roles in myeloma biology, such as CCND2 (Fig. 1f) . By contrast, a functionally inactive enantiomer of bio-JQ1 (bio-JQ1R, Supplementary Fig. 3a) did not produce significant Chem-seq signals (Supplementary Fig. 3b,c) . These results indicate that both live-cell-and cell-lysate-based Chem-seq approaches (Fig. 1a) can be used to uncover the interactions of small molecules with their chromatin targets across the human genome. Of note, JQ1 is known to displace BET bromodomains from the genome, but the ability to detect the bio-JQ1/BRD complex on chromatin is likely made possible by covalent tethering of these proteins to chromatin during fixation (Supplementary Fig. 4) .
We next investigated the extent to which Chem-seq and ChIP-seq signals overlap (Fig. 2) . The pattern of JQ1 occupancy was best associated with the pattern of BRD4 occupancy (Fig. 2a) . Pearson correlation analysis also showed that bio-JQ1 signals were most highly correlated with BRD4, somewhat less frequently with BRD2 and much less frequently with BRD3 (Fig. 2b) . We then developed a general linear model to identify genomic regions with differential signal between bio-JQ1 Chem-seq and each of the BRD ChIP-seq data sets. We found that bio-JQ1 co-occupied nearly all regions (>99%) with BRD4 genome-wide across triplicate data sets, bio-JQ1 and BRD2 co-occupied 96% of all genomic sites, and bio-JQ1 and BRD3 co-occupied 63% of all genomic sites (Fig. 2c) . Inspection of gene tracks for regions differentially occupied by bio-JQ1 and the three BET proteins provided visual confirmation that bio-JQ1 tends to co-occupy enhancers where there are substantial BRD4 signals and lower signals for BRD2 and BRD3 (Fig. 2d) . The pattern of BRD3 genome occupancy differed most from that of the other two BET proteins (Fig. 2a-c) , because of pronounced signals at a subset of core promoter sites (Fig. 2e) . Similar results were obtained with an alternative BRD3 ChIP antibody directed against a different epitope of this protein (Supplementary Fig. 5 ). Taken together, these results indicate that the pattern of JQ1 occupancy of chromatin is most strongly correlated with that of BRD4 in MM1.S cells, npg l e t t e r s consistent with the relative affinities of JQ1 for these BET proteins previously established in vitro 27 .
To extend the Chem-seq method to other drug classes, we initially focused on AT7519, an inhibitor of the cyclin-dependent kinase CDK9 (ref. 28) , which is associated with the transcription apparatus at promoters. CDK9 phosphorylation of RNA Pol II and various transcription pause control factors stimulates active elongation 29 . We first confirmed that CDK9 co-occupies the promoters of active genes with RNA Pol II by using ChIP-seq (Fig. 3a,b) . CDK9 is a core component of the positive transcription elongation factor, p-TEFb 29 , and its inhibition would be expected to affect the levels of elongating RNA Pol II, which is located across the body of genes, to a much greater extent than the levels of initiating RNA Pol II, located at the transcription start site (TSS). Indeed, treatment of MM1.S cells with AT7519 was found to cause a reduction in the level of elongating RNA Pol II based on examination of individual gene tracks (Fig. 3c) and on analysis of the ratio of initiating versus elongating RNA Pol II molecules at active genes throughout the genome (Fig. 3d) . We next generated a retrievable biotinylated derivative of AT7519 (Fig. 3e) . The biotinylated compound did not enter cells as readily as AT7519 (Fig. 3f,g ), so we used the in vitro Chem-seq method to investigate binding of bio-AT7519 to chromatin genome-wide. The results show that bio-AT7519 Chem-seq signals occur frequently at sites occupied by CDK9 (Fig. 3h,i) . The bio-AT7519 Chem-seq signals were weaker than those observed for bio-JQ1, which may reflect differences in accessibility, association constants or ligandreceptor sensitivity to sample preparation. Nonetheless, there was a correlation between bio-AT7519 occupancy and CDK9 occupancy genome-wide (Supplementary Fig. 6a ). There was also a substantial number of sites that were not co-occupied by bio-AT7519 and CDK9; it is possible that this was because of the relatively weak signals we obtained for bio-AT7519 Chem-seq or because AT7519 can inhibit other kinases 28, 30 that may occupy other genomic sites (Supplementary Fig. 6b ). Notably, a comparison of the Chem-seq data for bio-AT7519 and bio-JQ1 with ChIP-seq data for various components of the transcription apparatus (CDK7, CDK8, CDK9, RNA Pol II, Mediator and BRD4) revealed that bio-AT7519 was most often associated with CDK9, whereas bio-JQ1 was most often associated with BRD4 (Supplementary Fig. 6c ). These results suggest that Chem-seq can be useful for identifying the genomic binding sites of kinase inhibitors.
To further extend the Chem-seq method to other drug classes, we investigated how the DNA intercalator psoralen interacts with genomic DNA in vivo. Recent studies have shown that psoralen preferentially intercalates at the TSS of active genes 31, 32 . We used the in vivo Chem-seq method with biotinylated psoralen (bio-psoralen) (Fig. 3j) to explore this observation genome-wide in MM1.S cells. The results confirm that bio-psoralen preferentially binds to the TSS of active genes (Fig. 3k-m) . Thus, Chem-seq can detect local enrichment of DNA intercalating agents throughout the human genome.
A broad range of drugs should generally be amenable to biotinylation and Chem-seq analysis. The design and synthesis of biotinylated probes can be informed by structural data from drug-target complexes; such X-ray structures allow the identification of suitable attachment positions that can be covalently linked to the biotin moiety and that remain freely accessible in the complex. Suitable attachment points could also be inferred from structure-activity relationship data derived from structurally related compounds. If such data are not available, several attachment sites can be selected for biotinylation, and the derived probes can be tested experimentally to see if they remain bound to the target. Points of attachment can either be provided by functional groups already present in the drug molecule or may be obtained through chemical modification of the compound structure, such as alkylation or addition of amide or ester linkages. npg l e t t e r s Finally, as there is an expanding interest in elucidating the mechanisms of action of many drugs, biotinylated versions of such compounds are increasingly becoming commercially available.
In summary, Chem-seq provides a method to identify the sites bound by small chemical molecules throughout the genome. When combined with other global analysis methods such as ChIP-seq, Chem-seq provides an approach to investigate the direct, genome-wide effects of therapeutic modalities. Mapping the global interactions of a chemical entity with chromatin genome-wide should provide insights into the mechanisms by which small molecules perturb gene expression programs.
MeTHoDs
Methods and any associated references are available in the online version of the paper.
Accession codes. Chem-seq and ChIP-seq data, GEO: GSE44098 and GSE43743, respectively. The QC metrics for Chem-seq data sets are summarized in Supplementary Genome-wide occupancy analysis of drug target proteins (ChIP-seq). ChIP coupled with massively parallel DNA sequencing (ChIP-seq) was performed as previously described 33 . The following antibodies were used for ChIP: anti-BRD4 (Bethyl Labs, A301-985A), anti-BRD2 (Cell signaling, 5848), anti-BRD3 (Bethyl Labs, A302-367A and A302-368A), anti-MED1 (Bethyl Labs, A300-793A), anti-H3K27Ac (Abcam, ab4729), anti-RNA-Pol II (Santa Cruz, sc-899), anti-CTCF (Millipore, 07-729) and anti-CDK9 (sc-484). For each ChIP, 10 µg of antibody was added to 3 ml of sonicated nuclear extract. Illumina sequencing, library construction and ChIP-seq analysis methods were previously described 33 .
Expression of recombinant BRD4(1).
The first bromodomain of BRD4 was purified as a poly-histidine-tagged recombinant human protein expressed in Escherichia coli, as previously described 24 .
Differential scanning fluorimetry. Thermal melting experiments were carried out using a 7300 Real Time PCR machine (AB Applied Biosystems). Proteins were buffered in 10 mM HEPES pH 7.5, 500 mM NaCl and assayed in a 96-well plate at a final concentration of 1 µM in 20-µl volume. Compounds were added at a final concentration of 10 µM. SYPRO Orange (Molecular Probes) was added as a fluorescence probe at a dilution of 1:1,000. Excitation and emission filters for the SYPRO-Orange dye were set to 465 nm and 590 nm, respectively. The temperature was raised with a step of 4 °C per minute from 25 °C to 96 °C and fluorescence readings were taken at each interval. The observed temperature shifts, ∆Tm obs, were recorded as the difference between the transition midpoints of sample and reference (DMSO) wells containing protein without ligand in the same plate.
Isothermal titration calorimetry (ITC).
ITC was performed using an ITC200 microcalorimeter from MicroCal (Northampton, MA). All experiments were carried out at 25 °C while stirring at 1,000 r.p.m., in ITC buffer (50 mM HEPES pH 7.4 at 25 °C, 150 mM NaCl). The microsyringe was loaded with a solution of the protein sample (190 µM, in ITC buffer). All titrations were conducted using an initial injection of 0.2 µl, followed by 19 identical injections of 2 µl with a duration of 5 s (per injection) and a spacing of 90 s between injections. The heat of dilution was determined by independent titrations (protein into buffer) and was subtracted from the experimental data. The collected data were implicated in the MicroCal Origin software supplied with the instrument to yield enthalpies of binding (∆H) and binding constants. A single binding site model was employed. Dissociation constants and thermodynamic parameters are presented in Supplementary Figure 2c .
In vivo genome-wide occupancy analysis of biotinylated JQ1 (in vivo Chem-seq). Exponentially growing MM1.S cells (2 × 10 8 cells per sample) were treated simultaneously with either 5 µM biotinylated JQ1 (Bio-JQ1) or DMSO (vehicle) and 1% formaldehyde for 20 min in cell culture medium. Chemical cross-linking was terminated by addition of TRIS buffer, pH 7.5, to a final concentration of 300 mM TRIS. Cells were harvested using a silicon scraper, centrifuged, and the derived pellets washed three times with PBS. Cell nuclei were prepared as follows: cells were lysed in 50 mM HEPES, pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100 plus protease inhibitor cocktail 'complete' (Roche), and cell nuclei were washed once with 10 mM Tris-HCL, pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA and protease inhibitors. Nuclei were resuspended and sonicated in 50 mM HEPES-KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS (sonication buffer) and protease inhibitor cocktail at 18 W for 10 cycles (30 s each) on ice with 30-s intervals between cycles. Sonicated lysates were cleared by centrifugation and incubated for 16-20 h at 4 °C with magnetic streptavidin Dynabeads (MyOne Streptavidin T1, Invitrogen) (beads were blocked in PBS containing 0.5% BSA before this incubation step). Following incubation in nuclear sonicated lysate, beads were washed twice in sonication buffer, once in sonication buffer containing 500 mM NaCl, once in LiCl buffer (20 mM Tris-HCL, pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate), and once in 10 mM TRIS, pH 7.5, 0.1 mM EDTA. Bound protein-DNA complexes were subsequently eluted in 50 mM Tris-HCL, pH 8.0, 10 mM EDTA, 10% SDS at 65 °C for 15 min, and cross-links were reversed by overnight incubation of the eluate at 65 °C. Contaminating RNA and protein were digested by addition of RNase and Proteinase K, respectively, and the DNA purified as previously described 34 . Finally, purified DNA fragments were massively parallel sequenced and the sequencing data analyzed as described 33 .
In vitro genome-wide occupancy analysis of biotinylated JQ1 (in vitro Chem-seq). Exponentially growing, untreated MM1.S cells were fixed with 1% formaldehyde for 20 min in cell culture medium. Chemical cross-linking was terminated, cell nuclei prepared and sonicated nuclear lysate obtained as described above. Unlike in the in vivo protocol, however, Streptavidin Dynabeads were pre-incubated in PBS containing 0.5% BSA and either 200 µM biotinylated drug or vehicle (DMSO) for 6 h. Drug-bound beads were subsequently washed four times in PBS/0.5% BSA to remove unbound drug, and incubated in nuclear sonicated lysate for 16-20 h at 4 °C. All the following steps are identical to those described above (in vivo Chem-seq method).
In vitro genome-wide occupancy analysis using biotinylated AT7519 (in vitro Chem-seq). Exponentially growing, untreated MM1.S cells were fixed with 0.5% formaldehyde for 5 min in cell culture medium. Chemical cross-linking was terminated by addition of TRIS buffer, pH 7.5, to a final concentration of 300 mM TRIS. Cells were washed 3× in PBS and cell nuclei prepared as follows: cell nuclei were lysed in 50 mM HEPES, pH 7.5, 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% Triton X-100 plus protease inhibitor cocktail 'complete' (Roche), and cell nuclei were washed once with 10 mM Tris-HCL, pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA and protease inhibitors. Nuclei were resuspended and sonicated in 50 mM HEPES-KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5% NP-40, 0.5% Triton-X (sonication buffer). Pellets were sonicated at 9-12 W for 4 cycles (30 s each) in a Misonix sonicator on ice with 1-min rest intervals between cycles. Drug-bound beads were added to the cleared sonicate and the precipitation allowed to proceed for 12-18 h. Drug-bound beads were subsequently washed four times in sonication buffer, proteins eluted in 1% SDS, and cross-links were reversed by overnight incubation of the eluate at 65 °C in 1% SDS. Contaminating RNA and protein were digested by sequential incubation with RNase A and Proteinase K, and the DNA purified as previously described 34 . Purified DNA fragments were subjected to massively parallel sequencing (Illumina) and the sequencing data analyzed as described 33 .
Genome-wide occupancy analysis of biotinylated psoralen by Chem-seq. Cell nuclei were prepared from exponentially growing MM.S cells using the Nuclei EZ prep kit (Sigma). Nuclei were then resuspended in ice-cold PBS and directly incubated with 5 µM biotinylated psoralen or vehicle (DMSO) for 30 min at 4 °C. Nuclei were washed once in PBS and immediately irradiated at 360 nm for 30 min (Stratalinker) on ice. Nuclei were resuspended and sonicated in 50 mM HEPES-KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS (sonication buffer) and protease inhibitor cocktail at 18 W for 10 cycles (30 s each) on ice with 30 s intervals between cycles. Sonicated lysates were cleared by centrifugation and incubated for 16-20 h at 4 °C with magnetic Streptavidin Dynabeads (MyOne Streptavidin T1, Invitrogen) (beads were blocked in PBS containing 0.5% BSA before this incubation step). Following incubation in nuclear-sonicated lysate, beads were washed twice in sonication buffer, once in sonication buffer containing 500 mM NaCl, once in LiCl buffer (20 mM Tris-HCL, pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate), and once in 10 mM TRIS, pH 7.5, 0.1 mM EDTA. Bound protein-DNA complexes were subsequently eluted in 50 mM Tris-HCL, pH 8.0, 10 mM EDTA, 10% SDS and 10 mM Biotin, and the eluate incubated o/n at 65 °C. Contaminating RNA and protein were digested by addition of RNase and Proteinase K, respectively, and the DNA purified as previously described 34 . Finally, purified DNA samples were irradiated at 254 nm for 5 min (Stratalinker) to reverse psoralen-DNA cross-links, followed by library preparation, massively parallel DNA sequencing and analysis of sequencing data 33 .
